Advertisement

Ruxolitinib Reduces JAK2 p.V617F Allele Burden in Patients With Polycythemia Vera Enrolled in the RESPONSE Study

Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in JAK2 p.V617F allele burden in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.

 Ann Hematol

click me